Avacta engages in the provision of proprietary solutions to the healthcare sector. Avacta is developing next-gen biologics to improve the clinical outcome for the sizable proportion of solid tumour patients having “cold” tumours that do not have a durable response to checkpoint inhibitors alone. Avacta is addressing this need by combining two proprietary platforms – Affimers®, a best-in-class antibody mimetic and TMACTM, drug conjugates that are activated in the tumour microenvironment to release pro-inflammatory drugs that synergise with the Affimer checkpoint modulators.
Unit 20, Ash Way
Thorp Arch Estate
Wetherby, LS23 7FA
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
European Biotech Investor Day 2019
New York City,
August 1, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by